NCT04457544 Spontaneous Coronary Artery Dissection National Swiss Registry
| NCT ID | NCT04457544 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dr. Sophie Degrauwe |
| Condition | Spontaneous Coronary Artery Dissection |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2020-08-12 |
| Primary Completion | 2025-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2020-08-12 with a primary completion date of 2025-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Spontaneous coronary artery dissection (SCAD), is an underdiagnosed pathology, affecting predominantly young women without traditional cardiovascular risk factors and is associated with major adverse outcomes including myocardial infarction, cardiac arrest, or death. Timely diagnosis of SCAD as well as clinical follow-up are of the essence in this pathology associated with major cardiac adverse outcomes. Despite recent improvements in diagnosis and recognition of the importance of SCAD, it remains poorly studied and understood. In this context, we designed the SwissSCAD registry, a large, observational, prospective, cohort study, to describe the natural history of SCAD, its outcomes and its treatments.
Eligibility Criteria
Inclusion Criteria: * Subject is ≥18 years of age. * Patient presenting newly diagnosed SCAD or diagnosed with SCAD within the last 5 years. * Subject must be willing to sign a Patient Informed Consent (PIC). Exclusion Criteria: * Patient unwilling or unable to provide informed consent. * Patients with atherosclerotic or iatrogenic coronary dissection.
Contact & Investigator
Sophie Degrauwe, Dr
PRINCIPAL INVESTIGATOR
Hopitaux universitaires de Geneve
Frequently Asked Questions
Who can join the NCT04457544 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Spontaneous Coronary Artery Dissection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04457544 currently recruiting?
Yes, NCT04457544 is actively recruiting participants. Contact the research team at sophie.degrauwe@hcuge.ch for enrollment information.
Where is the NCT04457544 trial being conducted?
This trial is being conducted at Geneva, Switzerland.
Who is sponsoring the NCT04457544 clinical trial?
NCT04457544 is sponsored by Dr. Sophie Degrauwe. The principal investigator is Sophie Degrauwe, Dr at Hopitaux universitaires de Geneve. The trial plans to enroll 1,000 participants.